Stewart J A, Cassileth P A, Bennett J M, O'Connell M J
Vermont Regional Cancer Center, Burlington 05401.
Am J Clin Oncol. 1988 Dec;11(6):627-9. doi: 10.1097/00000421-198812000-00006.
Single-agent homoharringtonine (HH) was evaluated as induction therapy in 20 patients with advanced acute nonlymphocytic leukemia (ANLL) in a pilot study of the Eastern Cooperative Oncology Group (ECOG). HH was given by continuous intravenous (i.v.) infusion at 3.5 mg/m2 on the first day and at 6.0 mg/m2/day on days 2-8. Fourteen men and six women with a median age of 43 years were treated. Sixteen patients had clearing of peripheral blasts, 10 patients achieved marrow hypoplasia, and 2 patients had progressive disease. No complete remission occurred. Drug-induced hypotension was the most significant toxicity, causing a delay in treatment in 8 patients. The median survival was 15 weeks (range 1-65 weeks) from the start of HH treatment. Despite a definite antileukemic effect, HH as a single agent cannot be recommended as a useful salvage regimen in patients with far advanced ANLL.
在东部肿瘤协作组（ECOG）的一项初步研究中，对20例晚期急性非淋巴细胞白血病（ANLL）患者评估了单药高三尖杉酯碱（HH）作为诱导治疗的效果。HH于第1天以3.5 mg/m²持续静脉输注给药，第2 - 8天以6.0 mg/m²/天持续静脉输注给药。治疗了14名男性和6名女性，中位年龄为43岁。16例患者外周血原始细胞清除，10例患者达到骨髓增生低下，2例患者疾病进展。无完全缓解发生。药物性低血压是最显著的毒性反应，导致8例患者治疗延迟。从开始HH治疗起，中位生存期为15周（范围1 - 65周）。尽管HH有明确的抗白血病作用，但对于晚期ANLL患者，不推荐将HH作为单药用于有效的挽救治疗方案。
